Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
enprofylline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| N-methylated xanthine derivatives | 1015 | 41078-02-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 88 % | |
| Vd (Volume of distribution) | 0.63 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.55 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 5.68 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| MeSH PA | D058914 | Purinergic Antagonists |
| MeSH PA | D058915 | Purinergic P1 Receptor Antagonists |
| MeSH PA | D058917 | Adenosine A2 Receptor Antagonists |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35523 | bronchodilator agent |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:49167 | anti-asthmatic drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.61 | acidic |
| pKa2 | 8.27 | acidic |
| pKa3 | 2.65 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Adenosine receptor A2a | GPCR | Ki | 4.49 | CHEMBL | |||||
| Adenosine receptor A1 | GPCR | Ki | 4.38 | CHEMBL | |||||
| Adenosine receptor A2b | GPCR | Ki | 5.33 | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | Ki | 4.03 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Enzyme | WOMBAT-PK | |||||||
| Adenosine receptor A1 | GPCR | Ki | 4.49 | CHEMBL | |||||
| Adenosine receptor A2a | GPCR | Ki | 4.49 | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | Ki | 4.19 | CHEMBL | |||||
| Adenosine receptor A1 | GPCR | Ki | 4.22 | CHEMBL | |||||
| Adenosine A2a receptor | GPCR | Ki | 4.04 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D04006 | KEGG_DRUG |
| C0059372 | UMLSCUI |
| CHEBI:126237 | CHEBI |
| CHEMBL279898 | ChEMBL_ID |
| DB00824 | DRUGBANK_ID |
| 1676 | PUBCHEM_CID |
| C034347 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4878 | INN_ID |
| DT7DT5E518 | UNII |
| A1BD3 | PDB_CHEM_ID |
| DT7DT5E518 | INXIGHT DRUGS |
Pharmaceutical products:
None